Search Results

FACIT-SWiP Functional Assessment of Chronic Illness Therapy - Satisfaction with Pharmacist Satisfaction with Pharmacist Scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACIT-SWiP measure: MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Satisfaction with Pharmacist (FACIT-SWiP) VERSION: 4 NUMBER OF ITEMS: 7 PATIENT POPULATION: Patients 18 and older receiving pharmacy care RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Satisfaction with Pharmacist Subscale TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-TS-G , FACIT-TS-PS , CCSQ DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-SWiP can be obtained by registering for permission. Users are not permitted to translate the FACIT-SWiP without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-SWiP may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Hernandez, L., Chang, C.H., Cella, D., Corona, M., Shiomoto, G., & McGuire, D.B. Development and validation of the Satisfaction with Pharmacist Scale. Pharmacotherapy 2000; 20(7): 837-843. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-TS-G Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction – General LEARN MORE FACIT-TS-PS Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - Patient Satisfaction LEARN MORE CCSQ Chemotherapy Convenience and Satisfaction Questionnaire LEARN MORE

View all available languages for this measure. BACK NFOSI-18 Languages Arabic Bengali Bulgarian Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French German Greek Gujarati Hebrew Hiligaynon Hindi Hungarian Italian Japanese Korean Latvian Malay Malayalam Marathi Norwegian Polish Portuguese Romanian Russian Slovak Spanish Swedish Tagalog Tamil Thai Turkish Ukrainian

Download this measure in English. BACK FOSI English Downloads Download PDF Download DOC

FACT-EF Functional Assessment of Cancer Therapy - Enteral Feeding For patients receiving Enteral Feeding LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-EF measure: MEASURE NAME: Functional Assessment of Cancer Therapy - Enteral Feeding (FACT-EF) VERSION: 1 NUMBER OF ITEMS: 20 PATIENT POPULATION: Patient population: Cancer patients 18 years and older undergoing enteral feeding RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: None TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. RELATED MEASURES: FACT-G , FACT-EGFRI-18 , FACT-Bl-Cys DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-EF can be obtained by registering for permission. Users are not permitted to translate the FACT-EF without permission from FACIT.org. Permission from FACIT.org to translate the FACT-EF may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE FACT-EGFRI-18 Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item Version LEARN MORE FACT-Bl-Cys Functional Assessment of Cancer Therapy – Bladder – Cystectomy LEARN MORE

FACT-ICM-17 Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17 Item Symptom Index For patients receiving immunotherapy treatment LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT-ICM-17 is a brief, validated measure developed to assess the most common, distressing, and clinically useful symptomatic ICM-related immune-related adverse events. It is appropriate for use in research as well as routine symptom monitoring and management. MEASURE NAME: Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17 Item Symptom Index VERSION: 1 NUMBER OF ITEMS: 17 PATIENT POPULATION: Cancer patients 18 years and older receiving immunotherapy treatment RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: ICM TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, total score possible RELATED MEASURES: FACT-ICM , FACT- G, FACT-RNT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-ICM-17 can be obtained by registering for permission. Users are not permitted to translate the FACT-ICM-17 without permission from FACIT.org. Permission from FACIT.org to translate the FACT-ICM-17 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Gudenkauf LM, Tometich DB, Hoogland AI, Li XY, Kirtane K, Small BJ, Barata A, Gonzalez BD, Chung CH, Shafique MR, Gray J, Khushalani NI, Postow MA, Cella D, Webster KA, Dicker AP, Jim HSL. Validation of the Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to Facilitate Implementation in Research and Clinical Care. Available at SSRN: https://ssrn.com/abstract=5034323 or http://dx.doi.org/10.2139/ssrn.5034323 Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL, Abdul Razak AR, Spreafico A, Sridhar SS, Leighl N, Butler MO, Hogg D, Sacher A, Oza AM, Al-Agha R, Maurice C, Chan CT, Shapera S, Feld JJ, Nisenbaum R, Webster K, Cella D, Parsons J. Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer. 2020 Apr 1;126(7):1550-1558. doi: 10.1002/cncr.32692. Epub 2020 Jan 8. PMID: 31914209. Webster KA, O’Connor ML, Hansen AR, Kircher S, Jim HSL, Dicker AP, Janda M, Ala-leppilampi K, Bingham CO III, Feliciano J, Henry NL, Steffen McLouth LE, Cella D. Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. J Cancer Metastasis Treat 2020;6:8. http://dx.doi.org/10.20517/2394-4722.2019.38. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-ICM Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy LEARN MORE

FACT-Br-CI Functional Assessment of Cancer Therapy – Brain Cognitive Index For patients with Brain cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT-Br-CI measures self-reported cognition in patients with brain cancer. Studies that included the FACT-Br could be retrospectively analyzed to assess subjective cognitive outcomes, enriching the information from prior research. Integration of the FACT-Br-CI in routine clinical care may be an efficient method of monitoring cognition. MEASURE NAME: Functional Assessment of Cancer Therapy – Brain Cognitive Index (FACT-Br-CI) VERSION: 4 NUMBER OF ITEMS: 9 PATIENT POPULATION: Brain cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Cognitive Index TIME FOR COMPLETION: 5 minutes SCORING: Manual scoring template, some items are reverse scored. RELATED MEASURES: FBrSI , NFBrSI-24 , FACT-Br DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Br-CI can be obtained by registering for permission. Users are not permitted to translate the FACT-Br-CI without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Br-CI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Zarrella GV, Perez A, Dietrich J, Parsons MW. Reliability and validity of a novel cognitive self-assessment tool for patients with cancer. Neurooncol Pract . 2021 Jul 21;8(6):691-698. doi: 10.1093/nop/npab045. PMID: 34777838; PMCID: PMC8579089. Weitzner, M.A., Meyers, C.A., Gelke, C., Byrne, K., Cella, D.F., & Levin, V.A. The Functional Assessment of Cancer Therapy (FACT) Scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995; 75(5): 1151-1161. Thavarajah, N., Bedard, G., Zhang, L., Cella, D., Beaumont, J., Tsao, M., Barnes, E., Danjoux, C., Sahgal, A., Soliman, H., & Chow, E. The Functional Assessment of Cancer Therapy – Brain (FACT-Br) for assessing quality of life in patients with brain metastases: A comparison of recall periods. Journal of Pain Management 2013; 6(3): 223-234. Thavarajah, N., G., Zhang, L., Cella, D., Beaumont, J. Tsao, M., Barnes, E., Danjoux, C., Sahgal, A., Soliman, H., & Chow, E. Psychometric validation of the functional assessment of cancer therapy—brain (FACT-Br) for assessing quality of life in patients with brain metastases Supportive Care in Cancer 2014; 22 (4): 1017-1028. doi: 10.1007/s00520-013-2060-8. Verhaak, E., Schimmel, W. C., Sitskoorn, M. M., Bakker, M., Hanssens, P. E., & Gehring, K. (2019). Multidimensional assessment of fatigue in patients with brain metastases before and after Gamma Knife radiosurgery. Journal of neuro-oncology , 144 (2), 377-384. Verhaak, E., Gehring, K., Hanssens, P. E., & Sitskoorn, M. M. (2019). Health-related quality of life of patients with brain metastases selected for stereotactic radiosurgery. Journal of neuro-oncology , 143 (3), 537-546. Verhaak, E., Schimmel, W. C., Gehring, K., Emons, W. H., Hanssens, P. E., & Sitskoorn, M. M. (2020). Health-related quality of life after Gamma Knife radiosurgery in patients with 1–10 brain metastases. Journal of Cancer Research and Clinical Oncology , 1-11. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FBrSI Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 15 Item Version LEARN MORE NRBrSI-24 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 24 Item Version LEARN MORE FACT-Br Functional Assessment of Cancer Therapy – Brain LEARN MORE

View all available languages for this measure. BACK FACIT-SWiP Languages Dutch English Japanese Spanish

NFBrSI-24 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 24 Item Version For patients with Brain cancer; A FACT/NCCN-Brain Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The NCCN-FACT Brain Symptom Index-24 (NFBrSI-24) is an index of the symptoms in advanced brain tumors perceived as most important by both patients and clinicians and improves upon existing measures of brain tumor symptoms through better satisfaction of regulatory requirements for measure development. The findings in development suggest good reliability and validity, indicating that the NFBrSI-24 is a promising brief assessment of high priority advanced brain tumor symptoms for research and clinical settings. MEASURE NAME: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 24 Item Version (NFBrSI-24) VERSION: 2 NUMBER OF ITEMS: 24 PATIENT POPULATION: Brain cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side-Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-Br , FBrSI , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFBrSI-24 can be obtained by registering for permission. Users are not permitted to translate the NFBrSI-24 without permission from FACIT.org. Permission from FACIT.org to translate the NFBrSI-24 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Lai, J-S. Cella, D. Beaumont, J., Jensen, S. Development of a Symptom Index for Patients with Primary Brain Tumors. Value in Health 2014; 17: 62-69. doi: 10.1016/j.jval.2013.11.006. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., & Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Br Functional Assessment of Cancer Therapy – Brain LEARN MORE FBrSI Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 15 Item Version LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

FACT-AntiA Functional Assessment of Cancer Therapy – AntiAngiogenesis For patients receiving Anti-Angiogenesis therapy LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-AntiA measure: MEASURE NAME: Functional Assessment of Cancer Therapy – AntiAngiogenesis (FACT-AntiA) VERSION: 4 NUMBER OF ITEMS: 50 PATIENT POPULATION: Patient population: Cancer patients 18 years and older receiving anti-angiogenesis treatment RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, AntiAngiogenesis Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT/GOG-NTX , FACT-BRM , FACT-BMT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-AntiA can be obtained by registering for permission. Users are not permitted to translate the FACT-AntiA without permission from FACIT.org. Permission from FACIT.org to translate the FACT-AntiA may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Kaiser K., Beaumont J.L., Webster K., Yount S.E., Wagner L.I., Kuzel T.M., Cella D. Development and validation of the Functional Assessment of Cancer Therapy – Antiangiogenesis subscale. Cancer Med 2015; May 4(5): 690-698. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT/GOG-NTX Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity LEARN MORE FACT-BRM Functional Assessment of Cancer Therapy - Biologic Response Modifiers LEARN MORE FACT-BMT Functional Assessment of Cancer Therapy - Bone Marrow Transplantation LEARN MORE

CCSQ Chemotherapy Convenience and Satisfaction Questionnaire LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Chemotherapy Convenience and Satisfaction Questionnaire (CCSQ) is comprised of two versions. The first is administered prior to initiating therapy and captures patients’ expectations on two domains: Chemotherapy Concerns (5 items) and Chemotherapy Convenience (3 items). The second version is administered while patients are on therapy (i.e., all post- Baseline Assessments) and includes three domains: Chemotherapy Concerns (5 items), Chemotherapy Convenience (3 items), and Chemotherapy Satisfaction (4 items). While its validity has been explored in multiple clinical trials, research into the relationship between the subscale scores and clinical variables should be explored in the future to further establish the measure’s validity. MEASURE NAME: Chemotherapy Convenience and Satisfaction Questionnaire (CCSQ) VERSION: 3 - Baseline 6 - On Therapy NUMBER OF ITEMS: 11 - Baseline 15 - On Therapy + Resource Utilization PATIENT POPULATION: Cancer patients 18 years and older receiving chemotherapy RECALL PERIOD: None RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Baseline: Chemotherapy Concerns, Chemotherapy Convenience On Therapy: Chemotherapy Concerns, Chemotherapy Convenience, Chemotherapy Satisfaction TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template. Subscale scores and total scores possible. Not all items are included in the total score - see scoring template for details. RELATED MEASURES: FACIT-TS-G , FACIT-TS-PS , FACT-Cog DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the CCSQ can be obtained by registering for permission. Users are not permitted to translate the CCSQ without permission from FACIT.org. Permission from FACIT.org to translate the CCSQ may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Yost K., Hahn E., Cella D. A new measure of chemotherapy convenience and satisfaction: the CCSQ. Journal of Clinical Oncology 2005; 23:538a. Saltz L., Badarinath S., Dakhil S., Bienvenu B., Harker W.G., Birchfield G., Tokaz L.K., Barrera D., Conkling P.R., O'Rourke M.A., Richards D.A., Reidy D., Solit D., Vakiani E., Capanu M., Scales A., Zhan F., Boehm K.A., Asmar L., Cohn A. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clinical Colorectal Cancer 2012; Jun 11(2):101-11. Chua D.T., Yiu H.H., Seetalarom K., Ng A.W., Kurnianda J., Shotelersuk K., Krishnan G., Hong R.L., Yang M.H., Wang C.H., Sze W.K., Ng W.T. Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. Head & Neck 2012; Sep 34(9):1225-30. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-TS-G Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction – General LEARN MORE FACIT-TS-PS Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - Patient Satisfaction LEARN MORE FACT-Cog Functional Assessment of Cancer Therapy - Cognitive Function LEARN MORE

FBrSI Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 15 Item Version For patients with Brain cancer; a FACT-Brain Symptom Index (a subset of FACT-Br containing 15 items) LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FBrSI measure: MEASURE NAME: Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 15 Item Version (FBrSI) VERSION: 4 NUMBER OF ITEMS: 15 PATIENT POPULATION: Brain cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Brain Cancer Subscale TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores available. SAS/SPSS algorithms available RELATED MEASURES: FACT-Br , NFBrSI-24 , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FBrSI can be obtained by registering for permission. Users are not permitted to translate the FBrSI without permission from FACIT.org. Permission from FACIT.org to translate the FBrSI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Br Functional Assessment of Cancer Therapy – Brain LEARN MORE NFBrSI-24 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 24 Item Version LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

Download this measure in English. BACK NFHNSI-22 English Downloads Download PDF Download DOC